The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Molecular Biology of Neuroblastoma
Abstract
PURPOSE AND RESULTS: Neuroblastoma, the most common solid extracranial neoplasm in children, is remarkable for its clinical heterogeneity. Complex patterns of genetic abnormalities interact to determine the clinical phenotype. The molecular biology of neuroblastoma is characterized by somatically acquired genetic events that lead to gene overexpression (oncogenes), gene inactivation (tumor suppressor genes), or alterations in gene expression. Amplification of the MYCN proto-oncogene occurs in 20% to 25% of neuroblastomas and is a reliable marker of aggressive clinical behavior. No other oncogene has been shown to be consistently mutated or overexpressed in neuroblastoma, although unbalanced translocations resulting in gain of genetic material from chromosome bands 17q23-qter have been identified in more than 50% of primary tumors. Some children have an inherited predisposition to develop neuroblastoma, but a familial neuroblastoma susceptibility gene has not yet been localized. Consistent areas of chromosomal loss, including chromosome band 1p36 in 30% to 35% of primary tumors, 11q23 in 44%, and 14q23-qter in 22%, may identify the location of neuroblastoma suppressor genes. Alterations in the expression of the neurotrophins and their receptors correlate with clinical behavior and may reflect the degree of neuroblastic differentiation before malignant transformation. Alterations in the expression of genes that regulate apoptosis also correlate with neuroblastoma behavior and may help to explain the phenomenon of spontaneous regression observed in a well-defined subset of patients. CONCLUSION: The molecular biology of neuroblastoma has led to a combined clinical and biologic risk stratification. Future advances may lead to more specific treatment strategies for children with neuroblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,262
Association of Multiple Copies of the N-myc Oncogene with Rapid Progression of Neuroblastomas
Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., & Hammond, D. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510313131802 · Cited by 2,010
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells
Günthert, U., Hofmann, M., Rudy, W., Reber, S., Zöller, M., Hauβmann, I., Matzku, S., Wenzel, A., Ponta, H., & Herrlich, P. (1991) · Cell · doi:10.1016/0092-8674(91)90403-l · Cited by 1,654
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Schwab, M., Alitalo, K., Klempnauer, K.-H., Varmus, H. E., Bishop, J. M., Gilbert, F., Brodeur, G., Goldstein, M., & Trent, J. (1983) · Nature · doi:10.1038/305245a0 · Cited by 1,407
The trk Proto-Oncogene Product: a Signal Transducing Receptor for Nerve Growth Factor
Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., & Parada, L. F. (1991) · Science · doi:10.1126/science.1850549 · Cited by 1,379
Biedler, J. L., Helson, L., & Spengler, B. A. (1973) · PubMed · Cited by 1,295
Targeted expression of MYCN causes neuroblastoma in transgenic mice
Weiss, W. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.2985 · Cited by 870
Cited by
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038
Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509
Self-citationIFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway
Fulda, S., & Debatin, K.-M. (2002) · Oncogene · doi:10.1038/sj.onc.1205255 · Cited by 260
Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., & Seeger, R. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj330 · Cited by 237
Self-citationIdentification of epigenetically regulated genes that predict patient outcome in neuroblastoma
Carén, H., Djos, A., Nethander, M., Sjöberg, R.-M., Kogner, P., Enström, C., Nilsson, S., & Martinsson, T. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-66 · Cited by 74
Metadata
- Authors
- Maris, J. M., & Matthay, K. K.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-07
- Volume
- 17
- Issue
- 7
- Pages
- 2264-2264
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1951128322
- Cited by
- 639
- References
- 110
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Biology of Neuroblastoma. https://app.cochat.ai/papers/10.1200/jco.1999.17.7.2264
- The paper
- Maris, J. M., & Matthay, K. K. (1999). Molecular Biology of Neuroblastoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.7.2264
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
